I-Hyaluronate evunyelweyo isetyenziswe kwi-Viscosupplementation
I-Supartz, isisombululo se-sodium hyaluronate, enye ye-hyaluronates esetyenziswe kwi- viscosupplementation . I-Supartz ijojowe ngqo kwi-knee joint ukuze kubuyiselwe iipropati zokugcoba kunye nokuhlanjululwa kwe-synovial fluid (oko kukuthi, umbane ohlangeneyo). I-hyaluronate ye-sodium esetyenziswe kwi-Supartz ikhutshwe kwi-combs combs. I-hyaluronate ye-sodium i-polysaccharide equle iiyunithi eziphinda zichazwe kwi-glucuronic acid kunye ne- N-acetylglucosamine .
Ukuvunyelwa kweSupartz neSupartz Fx
I-Supartz yavunywa yi-US FDA ngoJanuwari 24, 2001 ukunyanga kwe-knee osteoarthritis kwizigulane ezingaphumeleli ukufumana uncedo olwaneleyo kunye nokunyanga okulondolozayo, kubandakanya ukuzivocavoca, unyango lomzimba, unyango lwezilonda, izixhobo zokuhamba , kunye neepakethe ezishisayo okanye ezibandayo . Ukusetyenziswa kwamanye amalunga kuphandwa. I-Supartz isetyenzisiwe eJapan ukususela ngo-1987. Ijojowe kanye ngeveki umjikelezo weeveki ezi-5. Ezinye izigulane zinokuphendula emva kweentsuku ezi-3.
Ngo-Oktobha 12, 2015, iBooventus, umenzi we-Supartz, wamemezela ukuqaliswa kwe-Supartz Fx (10 mg ye-hyaluronate ye-sodium echithwe kwi-1.0% ye-saline yemvelo), ene-ileyali eyandisiweyo evela kwi-Supartz yasekuqaleni, evumela ukujikelezwa kweejokelelo. Nangona iileyibhile yokhuseleko yanda kwimizila yokuphindaphinda, ukuphumelela kwemijikelezo yokuphindaphinda akukasekwa.
Izilumkiso kunye nokuqapha
I-Supartz ayifanele ilawulwe kuyo nayiphi na isigulane esino-hypersensitive eyaziwayo kwimveliso ye-sodium hyaluronate.
Ulumkiso kufuneka lisetyenziswe xa unyanga izigulane ezinolwazi olusasaziwayo kumaprotheni, amaqanda, okanye iintsiba. Izigulane ezineentsholongwane okanye izifo zesikhumba kwindawo ekuya kunikwa ngayo umjovo akufanele iphathwe ngeSupartz.
Ukhuseleko kunye nokusebenza kweSupartz akuzange kusekwe kwabasetyhini abakhulelweyo, nakwabasetyhini abakhulayo.
Ukusetyenziswa kwayo akuzange kufundwe kubantwana.
Iziphumo eziPhakathi
Iziphumo eziqhelekileyo okanye iziganeko ezimbi ezinxulumene neSupart zibandakanya:
- Intlungu ehlangeneyo ngaphandle kokuvuvukala
- Umqolo obuhlungu
- Intlungu engezizo
- Ukusabela kwendawo yesifo
- Intloko
Ukuvuthwa okanye intlungu, eyokuphela kwexesha, inokuvela kwidibaniselwano ejoyiweyo neSupartz. Izigulane zikwacetyiswa ukuba ziphephe izenzo ezinzima okanye ezithwala ubunzima kwiiyure ezingama-48 zilandelayo.
Ngaphantsi
Uhlalutyo lwezilingo ezi-5 ezilungiselelwe kakuhle zonyango azibonakali mmahluko omkhulu phakathi kweSpartz kunye namaqela okulawula ngokwemiba emibi. Nangona ukhuseleko lweSupart kunye nezinye i-viscosupplements luye lwaphakanyiswa zizifundo zeklinikhi, uphunyezwe ngempumelelo. Ngokubhekiselele ekusebenzeni, iConfrane Review yagqiba ukuba i-viscosupplementation iphumelela ngakumbi kune-placebo, kodwa kukho ezinye iingcaphephe ezange zifinyelele ekuqinisekiseni ukuba iilenki zinika intlungu enkulu.
Imithombo:
Supartz Fx. Ulwaziso loLwazi. Bioventus. http://www.supartzfx.com/wp-content/uploads/2015/07/SUPARTZ_FX_Package_Insert.pdf
I-Bioventus ivula i-Supartz Fx Ngoku ngeLayibhile yoKhuseleko ewandisiweyo yokuphindaphinda ii-Cycle Injection kwi-Knee Osteoarthritis. Oktobha 12, 2015.
http://www.bioventusglobal.com/news/press-releases/bioventus-launches-supartz-fx%E2%84%A2-noku-ngaxutywanga-
I-Hyaluronic acid (i-Supartz): ukuhlaziywa kokusetyenziswa kwayo kwi-osteoarthritis yamadolo. IParaman MP. Iziyobisi kunye nokuguga. Novemba 2010.
http://www.ncbi.nlm.nih.gov/pubmed/20964466